Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

OP95 Anti-BRCA2 (Ab-1) Mouse mAb (2B)

Overview

Replacement Information

Key Spec Table

Species ReactivityHostAntibody Type
HMMonoclonal Antibody

Products

Catalogue NumberPackaging Qty/Pack
OP95-100UGCN Glass bottle 100 μg
Description
OverviewRecognzies the ~460 kDa BRCA2 protein in cells expressing a wild type BRCA2 gene. Sold under license of U.S. Patent 5,753,441 and 6,162,897.
Catalogue NumberOP95
Brand Family Calbiochem®
SynonymsAnti-Breast Cancer Susceptibility Protein
References
ReferencesAndres, J.L., et al. 1998. Oncogene 16, 2229.
Chen, J., et al. 1998. Mol. Cell 2, 317.
Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 5287.
Marmorstein, L.Y., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 13869.
Connor, F., et al. 1997. Nat. Genet. 17, 423.
Sharan, S.K., et al. 1997. Nature 386, 804.
Ludwig, T., et al. 1997. Genes Dev. 11, 1226.
Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 6927.
Rajan, J.V., et al. 1997. Dev. Biol. 184, 385.
Suzuki, A., et al. 1997. Genes Dev. 11, 1242.
Wong, A.K.C., et al. 1997. J. Biol. Chem. 272, 31941.
Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin. Oncol. 23, 1.
Goggins, M., et al. 1996. Cancer Res. 56, 5360.
Stratton, M.R. 1996. Hum. Mol. Genet. 5, 1515.
Tavtigian, S.V., et al. 1996. Nat. Genet. 12, 333.
Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 13078.
Spillman, M.A. and A.M. Bowcock. 1996. Oncogene 13, 1639.
Vaughn, J.P., et al. 1996. Cancer Res. 56, 4590.
Wooster, R., et al. 1995. Nature 378, 789.
Product Information
DeclarationSold under license of U.S. Patents 5,837,492 and 6,124,104.
FormLiquid
FormulationIn PBS.
Positive controlMCF7 cells
Preservative≤0.1% sodium azide
Quality LevelMQ100
Applications
Key Applications Immunoblotting (Western Blotting)
Immunoprecipitation
Application NotesImmunoblotting (2 µg/ml)
Immunoprecipitation (2 µg)
Application CommentsThe CAPAN-1 cell line, which has 6174delT mutation in the single BRCA2 allele, expresses a truncated BRCA2 protein of 230 kDa that contains the Anti-BRCA2 epitope and retains RAD51 binding but has lost p53 binding. Full length BRCA2 protein will co-migrate on SDS-PAGE with the catalytic subunit of DNA PK which can be detected using Anti-DNA PK, Cat. No. PC127. Antibody should be titrated for optimal results in individual systems.
Biological Information
Immunogena recombinant protein consisting of amino acids 1651-1821 of human BRCA2 fused to GST
ImmunogenHuman
Clone2B
HostMouse
IsotypeIgG2b
Species Reactivity
  • Human
Antibody TypeMonoclonal Antibody
Concentration Label Please refer to vial label for lot-specific concentration
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Dry Ice Only
Toxicity Standard Handling
Storage -20°C
Do not freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
OP95-100UGCN 04055977209709

Documentation

Anti-BRCA2 (Ab-1) Mouse mAb (2B) SDS

Title

Safety Data Sheet (SDS) 

Anti-BRCA2 (Ab-1) Mouse mAb (2B) Certificates of Analysis

TitleLot Number
OP95

References

Reference overview
Andres, J.L., et al. 1998. Oncogene 16, 2229.
Chen, J., et al. 1998. Mol. Cell 2, 317.
Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 5287.
Marmorstein, L.Y., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 13869.
Connor, F., et al. 1997. Nat. Genet. 17, 423.
Sharan, S.K., et al. 1997. Nature 386, 804.
Ludwig, T., et al. 1997. Genes Dev. 11, 1226.
Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 6927.
Rajan, J.V., et al. 1997. Dev. Biol. 184, 385.
Suzuki, A., et al. 1997. Genes Dev. 11, 1242.
Wong, A.K.C., et al. 1997. J. Biol. Chem. 272, 31941.
Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin. Oncol. 23, 1.
Goggins, M., et al. 1996. Cancer Res. 56, 5360.
Stratton, M.R. 1996. Hum. Mol. Genet. 5, 1515.
Tavtigian, S.V., et al. 1996. Nat. Genet. 12, 333.
Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 13078.
Spillman, M.A. and A.M. Bowcock. 1996. Oncogene 13, 1639.
Vaughn, J.P., et al. 1996. Cancer Res. 56, 4590.
Wooster, R., et al. 1995. Nature 378, 789.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision12-November-2008 JSW
SynonymsAnti-Breast Cancer Susceptibility Protein
ApplicationImmunoblotting (2 µg/ml)
Immunoprecipitation (2 µg)
DescriptionPurified mouse monoclonal antibody generated by immunizing mice with the specified immunogen and fusing splenocytes with myeloma cells. Recognizes the ~460 kDa BRCA2 protein.
BackgroundInherited mutations in the BRCA2 gene enhances the risk of familial breast cancer with the neoplasia related to loss of the wild type allele. Human BRCA2 encodes a 3418 amino acid protein with little homology to any known proteins. Transcription of BRCA2 appears to be co-ordinately regulated with BRCA1 during proliferation and differentiation with low level expression in early G1 and maximal expression occurring during the G1/S transition of the cell cycle. While loss of BRCA2 is associated with early onset breast cancer, the gene is also critical for embryogenesis. Although some mice nullizygous for BRCA2 die during embryogenesis, there have been BRCA2 knock-out mice that do survive to adulthood, albeit with various defects particularly in DNA repair capability. Loss of BRCA2 expression in embryogenesis does not appear to affect apoptosis, per se, but proliferation is impaired, perhaps due to enhanced expression of p21WAF1. Although the precise role for BRCA2 is still to be determined, recent studies implicate BRCA2 in DNA repair and recombination processes due to association with p53 and Rad51 and co-localization with BRCA1. BRCA2 levels, as well as BRCA1 levels, decline following DNA damage and the decrease in BRCA2 accompanies activation of p53. Interestingly, BRCA2 appears capable of specifically inhibiting p53 transcriptional activity, which implicates BRCA2 as a mediator of cell cycle control and DNA repair.
HostMouse
Immunogen speciesHuman
Immunogena recombinant protein consisting of amino acids 1651-1821 of human BRCA2 fused to GST
Clone2B
IsotypeIgG2b
Specieshuman
Positive controlMCF7 cells
FormLiquid
FormulationIn PBS.
Concentration Label Please refer to vial label for lot-specific concentration
Preservative≤0.1% sodium azide
CommentsThe CAPAN-1 cell line, which has 6174delT mutation in the single BRCA2 allele, expresses a truncated BRCA2 protein of 230 kDa that contains the Anti-BRCA2 epitope and retains RAD51 binding but has lost p53 binding. Full length BRCA2 protein will co-migrate on SDS-PAGE with the catalytic subunit of DNA PK which can be detected using Anti-DNA PK, Cat. No. PC127. Antibody should be titrated for optimal results in individual systems.
Storage -20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
Toxicity Standard Handling
ReferencesAndres, J.L., et al. 1998. Oncogene 16, 2229.
Chen, J., et al. 1998. Mol. Cell 2, 317.
Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 5287.
Marmorstein, L.Y., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 13869.
Connor, F., et al. 1997. Nat. Genet. 17, 423.
Sharan, S.K., et al. 1997. Nature 386, 804.
Ludwig, T., et al. 1997. Genes Dev. 11, 1226.
Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 6927.
Rajan, J.V., et al. 1997. Dev. Biol. 184, 385.
Suzuki, A., et al. 1997. Genes Dev. 11, 1242.
Wong, A.K.C., et al. 1997. J. Biol. Chem. 272, 31941.
Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin. Oncol. 23, 1.
Goggins, M., et al. 1996. Cancer Res. 56, 5360.
Stratton, M.R. 1996. Hum. Mol. Genet. 5, 1515.
Tavtigian, S.V., et al. 1996. Nat. Genet. 12, 333.
Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 13078.
Spillman, M.A. and A.M. Bowcock. 1996. Oncogene 13, 1639.
Vaughn, J.P., et al. 1996. Cancer Res. 56, 4590.
Wooster, R., et al. 1995. Nature 378, 789.